Company intelligence / Profile preview

Bicycle Therapeutics

Cambridge, United Kingdombicycletherapeutics.com ↗

Ownership: Public · BCYC
Development stage: Phase 2

Overview

BT8009 advancing to Phase 2/3 registrational trial in metastatic bladder cancer (planned for Q1 2024); BT5528 showing preliminary signs of anti-tumor activity including a partial response; BT7480 in Phase I/II clinical trial

Therapeutic areas: OtherOncology
Modalities: Bicyclic peptides (Bicycle® molecules)Bicycle Toxin Conjugates (BTCs)Bicycle tumor-targeted immune cell agonists (TICAs)
Industry: Biotech

Drug pipeline

17 assets

zelenectide pevedotin

16 more assets in the full pipeline.

Request access →

Partnerships

Cancer Research UKvarious pharmaceutical partners (specific names not provided)

Financials

Market cap: $265.8M
Total revenue: $629K
Enterprise value: $-230.6M

Beyond the preview

Go deeper on Bicycle Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bicycle Therapeutics.

Explore the full profile